The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive ...

Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Transparency in dealing with the former president’s condition would serve the public interest by increasing awareness and ...

When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic ...

Elder Spencer Blanchard of Salem, Oregon, is serving a mission while battling neuroblastoma. "I can’t change that I have ...